Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment

    Summary
    EudraCT number
    2012-003370-10
    Trial protocol
    AT   DE   FR  
    Global end of trial date
    30 Mar 2015

    Results information
    Results version number
    v1(current)
    This version publication date
    13 Apr 2016
    First version publication date
    13 Apr 2016
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CQGE031X2202
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01688882
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Novartis Pharma AG
    Sponsor organisation address
    CH-4002, Basel, Switzerland,
    Public contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
    Scientific contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    30 Mar 2015
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    30 Mar 2015
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The primary objective was to demonstrate the efficacy of QGE031 240mg q2w relative to placebo at 12 weeks in patients with BP by reducing disease activity as determined by Clinical Global Assessment of Change (CGA-C) responder rate.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    30 Jan 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 1
    Country: Number of subjects enrolled
    France: 3
    Country: Number of subjects enrolled
    Germany: 7
    Country: Number of subjects enrolled
    Japan: 2
    Country: Number of subjects enrolled
    Taiwan: 5
    Country: Number of subjects enrolled
    United States: 2
    Worldwide total number of subjects
    20
    EEA total number of subjects
    11
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    5
    From 65 to 84 years
    15
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Part 1 was a multicenter, randomized, placebo-controlled study evaluating the efficacy, safety, PK and PD of multiple, subcutaneous doses of QGE031 in the treatment of patients with BP with disease refractory to oral steroid treatment. Patients were treated with QGE031 or placebo in a 2:1 ratio.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Carer

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    QGE031
    Arm description
    QGE031 240 mg Q2W s.c.
    Arm type
    Experimental

    Investigational medicinal product name
    QGE031
    Investigational medicinal product code
    QGE031
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    QGE031 240 mg subcutaneously every 2 weeks for 12 weeks

    Arm title
    Placebo
    Arm description
    Placebo to Match Q2W s.c.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Placebo
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo subcutaneously every 2 weeks for 12 weeks

    Number of subjects in period 1
    QGE031 Placebo
    Started
    13
    7
    Safety Follow-up
    11
    5 [1]
    Completed
    10
    6
    Not completed
    3
    1
         Adverse event, non-fatal
    1
    -
         Unsatisfactory therapeutic effect
    1
    1
         Administrative problems
    1
    -
    Notes
    [1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: [2] The one patient that discontinued was already switched to open-label QGE031 treatment.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    QGE031
    Reporting group description
    QGE031 240 mg Q2W s.c.

    Reporting group title
    Placebo
    Reporting group description
    Placebo to Match Q2W s.c.

    Reporting group values
    QGE031 Placebo Total
    Number of subjects
    13 7 20
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    4 1 5
        From 65-84 years
    9 6 15
        85 years and over
    0 0 0
    Age Continuous |
    Units: years
        arithmetic mean (standard deviation)
    63.7 ± 14.85 67.9 ± 14.6 -
    Gender, Male/Female
    Units: participants
        Male
    10 3 13
        Female
    3 4 7

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    QGE031
    Reporting group description
    QGE031 240 mg Q2W s.c.

    Reporting group title
    Placebo
    Reporting group description
    Placebo to Match Q2W s.c.

    Primary: Number of Patients that had a Clinical Global Assessment of Change (CGA-C) responder rate by Week 12

    Close Top of page
    End point title
    Number of Patients that had a Clinical Global Assessment of Change (CGA-C) responder rate by Week 12 [1]
    End point description
    Clinical Global Assessment of Change (CGA-C) responder rate was the responder rate at 12 weeks based on the CGA-C in bullous pemphigoid (BP). A patient with a CGA-C score of 3 or 4 indicating ‘at least marked improvement from baseline’ at 12 weeks was considered a responder. The CGA-C is an investigator assessment of change from baseline and is scored as follows: -4 = Very marked worsening (100% worsening); -3 = Marked worsening (67-99% worsening); -2 = Moderate worsening (34-66% worsening); -1 = Slight worsening (1-33% worsening); 1= Slight improvement (1-33% improvement); 2 = Moderate improvement (34-66% improvement); 3 = Marked improvement (67-99% improvement); 4 = Complete clearance (100% improvement) No statistical analysis was planned for this primary outcome
    End point type
    Primary
    End point timeframe
    12 weeks
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No intergroup analysis were performed
    End point values
    QGE031 Placebo
    Number of subjects analysed
    13
    7
    Units: number of participants
    8
    2
    No statistical analyses for this end point

    Secondary: Response based on Clinical Global Assessment of Change CGA-C score at 6 weeks

    Close Top of page
    End point title
    Response based on Clinical Global Assessment of Change CGA-C score at 6 weeks
    End point description
    Clinical Global Assessment of Change (CGA-C) responder rate was the responder rate at 6 weeks based on the CGA-C score in bullous pemphigoid (BP). A patient with a CGA-C score of 3 or 4 indicating marked improvement from baseline at 6 weeks was considered a responder. The CGA-C is an investigator assessment of change from baseline and is scored as follows: -4 = Very marked worsening (100% worsening); -3 = Marked worsening (67-99% worsening); -2 = Moderate worsening (34-66% worsening); -1 = Slight worsening (1-33% worsening); 1= Slight improvement (1-33% improvement); 2 = Moderate improvement (34-66% improvement); 3 = Marked improvement (67-99% improvement); 4 = Complete clearance (100% improvement)
    End point type
    Secondary
    End point timeframe
    6 weeks
    End point values
    QGE031 Placebo
    Number of subjects analysed
    13
    7
    Units: number of participants
    8
    2
    No statistical analyses for this end point

    Secondary: Number of Patients Investigator Global Assessment Score over 12 weeks

    Close Top of page
    End point title
    Number of Patients Investigator Global Assessment Score over 12 weeks
    End point description
    Investigator’s Global Assessment (IGA) - (scale of 0 to 4, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe)
    End point type
    Secondary
    End point timeframe
    Baseline (week 0), week 6 and week 12
    End point values
    QGE031 Placebo
    Number of subjects analysed
    13
    7
    Units: Number of participants
        Week 0 - IGA Score: 0
    0
    0
        Week 6 - IGA Score: 0
    1
    2
        Week 12 - IGA Score: 0
    1
    2
        Week 0 - IGA Score: 1
    0
    0
        Week 6 - IGA Score: 1
    4
    2
        Week 12 - IGA Score: 1
    5
    1
        Week 0 - IGA Score: 2
    0
    0
        Week 6 - IGA Score: 2
    4
    0
        Week 12 - IGA Score: 2
    1
    2
        Week 0 - IGA Score: 3
    4
    5
        Week 6 - IGA Score: 3
    2
    2
        Week 12 - IGA Score: 3
    4
    1
        Week 0 - IGA Score: 4
    9
    2
        Week 6 - IGA Score: 4
    0
    0
        Week 12- IGA Score: 4
    0
    0
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    18.0
    Reporting groups
    Reporting group title
    Treatment Period - QGE031 240mg q2w
    Reporting group description
    Treatment Period - QGE031 240mg q2w

    Reporting group title
    Treatment Period - Placebo
    Reporting group description
    Treatment Period - Placebo

    Reporting group title
    Treatment Period - Open-label QGE031
    Reporting group description
    Treatment Period - Open-label QGE031

    Reporting group title
    Treatment Period - Total
    Reporting group description
    Treatment Period - Total

    Reporting group title
    Follow-up Period - QGE031 240mg q2w
    Reporting group description
    Follow-up Period - QGE031 240mg q2w

    Reporting group title
    Follow-up Period - Placebo
    Reporting group description
    Follow-up Period - Placebo

    Reporting group title
    Follow-up Period - Open-label QGE031
    Reporting group description
    Follow-up Period - Open-label QGE031

    Reporting group title
    Follow-up Period - Total
    Reporting group description
    Follow-up Period - Total

    Serious adverse events
    Treatment Period - QGE031 240mg q2w Treatment Period - Placebo Treatment Period - Open-label QGE031 Treatment Period - Total Follow-up Period - QGE031 240mg q2w Follow-up Period - Placebo Follow-up Period - Open-label QGE031 Follow-up Period - Total
    Total subjects affected by serious adverse events
         subjects affected / exposed
    6 / 13 (46.15%)
    2 / 7 (28.57%)
    1 / 4 (25.00%)
    8 / 20 (40.00%)
    2 / 11 (18.18%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 18 (11.11%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    0
    0
    Injury, poisoning and procedural complications
    Meniscus injury
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arrhythmia
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiogenic shock
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Coronary artery disease
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cauda equina syndrome
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Gastrointestinal haemorrhage
         subjects affected / exposed
    2 / 13 (15.38%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    2 / 20 (10.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatic failure
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Respiratory failure
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Pemphigoid
         subjects affected / exposed
    3 / 13 (23.08%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    3 / 20 (15.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
    0 / 0
    3 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    1 / 13 (7.69%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    2 / 20 (10.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal sepsis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    2 / 13 (15.38%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    2 / 20 (10.00%)
    2 / 11 (18.18%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 18 (11.11%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 3
    0 / 2
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Diabetes mellitus
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Treatment Period - QGE031 240mg q2w Treatment Period - Placebo Treatment Period - Open-label QGE031 Treatment Period - Total Follow-up Period - QGE031 240mg q2w Follow-up Period - Placebo Follow-up Period - Open-label QGE031 Follow-up Period - Total
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    11 / 13 (84.62%)
    6 / 7 (85.71%)
    2 / 4 (50.00%)
    17 / 20 (85.00%)
    10 / 11 (90.91%)
    3 / 5 (60.00%)
    2 / 4 (50.00%)
    15 / 18 (83.33%)
    Vascular disorders
    Haematoma
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    0
    0
    1
    1
    0
    0
    1
    Chest discomfort
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    0 / 11 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    1
    Injection site haematoma
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Injection site pain
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    5
    6
    11
    0
    0
    0
    0
    Malaise
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Xerosis
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    1 / 11 (9.09%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    2 / 18 (11.11%)
         occurrences all number
    0
    1
    0
    1
    1
    1
    0
    2
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Cough
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Dyspnoea
         subjects affected / exposed
    1 / 13 (7.69%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    2 / 20 (10.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    1
    0
    2
    0
    0
    0
    0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    2 / 13 (15.38%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    2 / 20 (10.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    2
    0
    0
    2
    0
    0
    0
    0
    Investigations
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    0
    0
    1
    1
    0
    0
    1
    Blood triglycerides increased
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Eosinophil count increased
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Haemoglobin urine present
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Lipase increased
         subjects affected / exposed
    2 / 13 (15.38%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    2 / 20 (10.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    2
    0
    0
    2
    1
    0
    0
    1
    Neutrophil count increased
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Neutrophil morphology abnormal
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Staphylococcus test positive
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    White blood cells urine positive
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Injury, poisoning and procedural complications
    Accidental overdose
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Ligament sprain
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Tooth fracture
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Wound
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    0
    1
    1
    0
    0
    1
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Nervous system disorders
    Burning sensation
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Headache
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Paraesthesia
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Sciatic nerve palsy
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Sciatica
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    0 / 11 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    1
    Syncope
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Vascular dementia
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Lymphopenia
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Thrombocytosis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Eye disorders
    Conjunctivitis allergic
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Dry eye
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Aphthous stomatitis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Diarrhoea
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Gastrointestinal disorder
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Hepatobiliary disorders
    Hepatitis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Dry skin
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    2 / 20 (10.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    0
    1
    2
    1
    0
    0
    1
    Miliaria
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Pemphigoid
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    2 / 20 (10.00%)
    1 / 11 (9.09%)
    1 / 5 (20.00%)
    1 / 4 (25.00%)
    3 / 18 (16.67%)
         occurrences all number
    1
    0
    1
    2
    1
    1
    1
    3
    Pruritus
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    3 / 11 (27.27%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    3 / 18 (16.67%)
         occurrences all number
    1
    0
    0
    1
    3
    0
    0
    3
    Purpura senile
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Skin hyperpigmentation
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    0
    1
    1
    0
    0
    1
    Urticaria
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    0
    0
    1
    1
    0
    0
    1
    Renal and urinary disorders
    Glycosuria
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Endocrine disorders
    Cushingoid
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Musculoskeletal and connective tissue disorders
    Muscular weakness
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    Musculoskeletal stiffness
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Myalgia
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Infections and infestations
    Acarodermatitis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Cystitis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Furuncle
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Herpes zoster
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    Infection
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    0
    0
    1
    1
    0
    0
    1
    Ophthalmic herpes simplex
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Oral herpes
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Pneumonia
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Skin candida
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Urinary tract infection
         subjects affected / exposed
    2 / 13 (15.38%)
    1 / 7 (14.29%)
    0 / 4 (0.00%)
    3 / 20 (15.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    3
    1
    0
    4
    1
    0
    0
    1
    Metabolism and nutrition disorders
    Cachexia
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Diabetes mellitus
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Glucose tolerance impaired
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    Gout
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    0 / 11 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    1
    Hypercholesterolaemia
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Hyperglycaemia
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    0 / 4 (0.00%)
    0 / 20 (0.00%)
    1 / 11 (9.09%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    Hyperkalaemia
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 7 (0.00%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    Hypokalaemia
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    1
    2
    0
    0
    0
    0
    Hyponatraemia
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 7 (14.29%)
    1 / 4 (25.00%)
    1 / 20 (5.00%)
    0 / 11 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    1
    2
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Feb 2013
    Amendment 1: was generated in order to comply with a German health authority request relating to effective methods of contraception. Specifically,that the combined use of condoms and spermicides (foam/gel/film/cream/vaginal suppository)for contraception was not recommended in Germany. Therefore,the other described methods of contraception were to be used in Germany. The justification given was that since most of the spermicides are aliphatic, fat could make the condom leaky and potentially lead to unintentional pregnancy. The combination of these barrier methods of contraception has been accepted by other Health Authorities, and therefore changes in Section 4.2 pertain only to Germany. Other minor and administrative changes were made throughout the protocol for clarity and consistency.
    03 Apr 2013
    Amendment 2: was generated to comply with a Japanese health authority request given that this was the first multi-dosing study with QGE031 in Japan. Specifically,this related to the possibility of weekly unscheduled patient visits occurring during prednisone tapering, inclusion of blood sampling for hematology and clinical chemistry also during weeks 2 and 4, and clarification of the instructions provided to patients relating to epinephrine auto-injector use.Changes proposed within this amendment pertained to all countries.Other minor and administrative changes were made throughout the protocol for clarity and consistency.
    17 May 2013
    Amendment 3:was generated in response to a request from the French Health Authority(Agence nationale de sécurité du médicament et des produits de santé). Specifically,the protocol was revised to provide recommendations to Investigators regarding the treatment of adverse events. Changes contained within this amendment pertained to all countries.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    This study was stopped after Part 1 completed and was terminated because the predefined criteria of efficacy was not reached ( >50% better then placebo)
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 09:40:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA